Literature DB >> 16865288

Expression of E6/E7 mRNA from 'high risk' human papillomavirus in relation to CIN grade, viral load and p16INK4a.

Sonia Andersson1, Berit Hansson, Ingrid Norman, Vera Gaberi, Miriam Mints, Anders Hjerpe, Frank Karlsen, Bo Johansson.   

Abstract

Detection of E6/E7 mRNA expression with real-time nucleic acid sequence-based amplification assay (NASBA) method (PreTect HPV-Proofer) from high-risk types of human papillomaviruses (HR-HPV) were compared with the presence of viral load, determined with quantitative real-time PCR in 80 cervical samples. Results regarding positivity and typing were in agreement using the two methods. However, there was no correlation between viral loads for HPV 16 or 18/45 and oncogene expression. Among 15 women with low grade atypia detected at a population-based cytology screening, and scored as 'within normal limits' according to histopathology, 14% were positive for oncogene expression, whereas 71% were HR-HPV positive. A correlation was observed between HR-HPV oncogene expression and high scores of p16(INK4a) positivity. Since HPV-Proofer detects full-length E6/E7 mRNA, a positive result should correlate with presence of integrated HPV, loss of HPV replication and stabilized E6/E7 full-length mRNA expression. Such expression from integrated HR-HPV generates a high and stable expression of full-length E6 proteins, which explains why a positive HPV-Proofer result was independent of viral load and correlate with high expression of p16(INK4a). Thus, E6/E7 oncogene expression analysis yielded information, which is consistent with and will complement the results from a real-time PCR method in a clinical prognostic procedure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16865288

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  10 in total

1.  Detection of genomic amplification of the human telomerase gene TERC, a potential marker for triage of women with HPV-positive, abnormal Pap smears.

Authors:  Sonia Andersson; Pavani Sowjanya; Darawalee Wangsa; Anders Hjerpe; Bo Johansson; Gert Auer; Patti E Gravitt; Catharina Larsson; Keng-Ling Wallin; Thomas Ried; Kerstin Heselmeyer-Haddad
Journal:  Am J Pathol       Date:  2009-11       Impact factor: 4.307

2.  High risk HPV DNA subtypes and E6/E7 mRNA expression in a cohort of colposcopy patients from Northern Italy with high-grade histologically verified cervical lesions.

Authors:  Liverani Ca; Ciavattini A; Monti E; Puglia D; Mangano S; D I Giuseppe J; Zizzi A; Goteri G; Bolis G
Journal:  Am J Transl Res       Date:  2012-10-10       Impact factor: 4.060

Review 3.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

4.  Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix.

Authors:  Paola Cattani; Gian Franco Zannoni; Caterina Ricci; Sara D'Onghia; Ilaria Nausica Trivellizzi; Aldo Di Franco; Valerio G Vellone; Maria Durante; Giovanni Fadda; Giovanni Scambia; Giovanni Capelli; Rosa De Vincenzo
Journal:  J Clin Microbiol       Date:  2009-10-14       Impact factor: 5.948

5.  Human Papillomavirus E6/E7-Specific siRNA Potentiates the Effect of Radiotherapy for Cervical Cancer in Vitro and in Vivo.

Authors:  Hun Soon Jung; Nirmal Rajasekaran; Sang Yong Song; Young Deug Kim; Sungyoul Hong; Hyuck Jae Choi; Young Seok Kim; Jong-Sun Choi; Yoon-La Choi; Young Kee Shin
Journal:  Int J Mol Sci       Date:  2015-05-29       Impact factor: 5.923

6.  HPV16 DNA and integration in normal and malignant epithelium: implications for the etiology of laryngeal squamous cell carcinoma.

Authors:  X Chen; L Gao; E M Sturgis; Z Liang; Y Zhu; X Xia; X Zhu; X Chen; G Li; Z Gao
Journal:  Ann Oncol       Date:  2017-05-01       Impact factor: 32.976

Review 7.  Accuracy of mRNA HPV Tests for Triage of Precursor Lesions and Cervical Cancer: A Systematic Review and Meta-Analysis.

Authors:  Ana Cristina L Macedo; João Carlos N Gonçalves; Daniela Vicente Bavaresco; Antonio José Grande; Napoleão Chiaramonte Silva; Maria Inês Rosa
Journal:  J Oncol       Date:  2019-06-11       Impact factor: 4.375

8.  The potential of RNA as a target for national screening of pre-cancer.

Authors:  Frank Karlsen; Margaret Muturi; Cosmas Muyabwa; Lars E Roseng; Serge Bigabwa; Byamungu Chihongola; Lucy Muchiri
Journal:  J Public Health Afr       Date:  2018-12-21

Review 9.  Laboratory and clinical aspects of human papillomavirus testing.

Authors:  Paul K S Chan; María Alejandra Picconi; Tak Hong Cheung; Lucia Giovannelli; Jong Sup Park
Journal:  Crit Rev Clin Lab Sci       Date:  2012 Jul-Aug       Impact factor: 6.250

10.  MicroRNA-331-3p Suppresses Cervical Cancer Cell Proliferation and E6/E7 Expression by Targeting NRP2.

Authors:  Tomomi Fujii; Keiji Shimada; Aya Asano; Yoshihiro Tatsumi; Naoko Yamaguchi; Masaharu Yamazaki; Noboru Konishi
Journal:  Int J Mol Sci       Date:  2016-08-18       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.